DY
OREX

Dowling & Yahnke’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Dowling & Yahnke’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-68,381
Closed -$294K – 274
2016
Q2 		$294K Hold
68,381
– – 0.04% 238
2016
Q1 		$385K Buy
+68,381
New +$888K 0.05% 210
2014
Q4 		– Sell
-5,160
Closed -$220K – 266
2014
Q3 		$220K Buy
+5,160
New +$277K 0.03% 241

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dowling & Yahnke's OREX Position: Q3 2016 in Review

Dowling & Yahnke sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 68,381 shares — an estimated $294K sold.

Dowling & Yahnke first reported a position in OREX in Q3 2014 and held it in 3 quarters. The position peaked at $385K in Q1 2016. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

  • Dowling & Yahnke reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Dowling & Yahnke sold 68,381 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $294K.
  • Dowling & Yahnke first reported a position in Orexigen Therapeutics, Inc. in Q3 2014 and held it in 3 quarters.
  • Dowling & Yahnke's Orexigen Therapeutics, Inc. position peaked at $385K in Q1 2016.
  • 55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on Dowling & Yahnke's 13F filing for Q3 2016, filed 20 Oct 2016.